Lilly And Daiichi Bet On Premium Price For Effient Over Plavix
Executive Summary
Lilly and Daiichi Sankyo's newly approved platelet inhibitor Effient (prasugrel) will be priced at an 18 percent premium to Bristol-Myers Squibb's market leader Plavix, even though Effient carries a "black box" warning for bleeding risks, the drug makers disclosed on July 15